The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Rho GTPases and the Actin Cytoskeleton
Hall, A. (1998) · Science · doi:10.1126/science.279.5350.509 · Cited by 6,140
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt
Peso, L. D., González-Garcı́a, M., Page, C., Herrera, R., & Nuñez, G. (1997) · Science · doi:10.1126/science.278.5338.687 · Cited by 1,797
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. C., & Walsh, K. (2000) · Nature Medicine · doi:10.1038/79510 · Cited by 1,439
Wolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)
Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,078
Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 911
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Translational Control of p27 Kip1 Accumulation During the Cell Cycle
Hengst, L., & Reed, S. I. (1996) · Science · doi:10.1126/science.271.5257.1861 · Cited by 846
Protein Lipidation in Cell Signaling
Casey, P. J. (1995) · Science · doi:10.1126/science.7716512 · Cited by 774
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Differentiation Stage-Specific Inhibition of the Raf-MEK-ERK Pathway by Akt
Rommel, C., Clarke, B. A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., & Glass, D. J. (1999) · Science · doi:10.1126/science.286.5445.1738 · Cited by 758
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680
Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation In Animal Cells
James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C. W., Lucas, B. K., Levinson, A. D., & Marsters, J. C. (1993) · Science · doi:10.1126/science.8316834 · Cited by 630
Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation
Montagnoli, A., Fiore, F., Eytan, E., Carrano, A. C., Draetta, G. F., Hershko, A., & Pagano, M. (1999) · Genes & Development · doi:10.1101/gad.13.9.1181 · Cited by 597
Selective Inhibition of ras -Dependent Transformation by a Farnesyltransferase Inhibitor
Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., & Gibbs, J. B. (1993) · Science · doi:10.1126/science.8316833 · Cited by 579
Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., Desolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., et al. (1995) · Nature Medicine · doi:10.1038/nm0895-792 · Cited by 540
The Risk of Cancer in Users of Statins
Graaf, M. R., Beiderbeck, A. B., Egberts, A. C. G., Richel, D. J., & Guchelaar, H.-J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.027 · Cited by 528
Self-citationStatins as antioxidant therapy for preventing cardiac myocyte hypertrophy
Takemoto, M., Node, K., Nakagami, H., Liao, Y., Grimm, M., Takemoto, Y., Kitakaze, M., & Liao, J. K. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13350 · Cited by 491
le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
Olson, M. F., Paterson, H. F., & Marshall, C. J. (1998) · Nature · doi:10.1038/28425 · Cited by 464
Genetic determinants of p53-induced apoptosis and growth arrest.
Polyak, K., Waldman, T., He, T. C., Kinzler, K. W., & Vogelstein, B. (1996) · Genes & Development · doi:10.1101/gad.10.15.1945 · Cited by 459
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.
Keyomarsi, K., Sandoval, L. S., Band, V., & Pardee, A. B. (1991) · PubMed · Cited by 459
Karp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3361 · Cited by 443
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Alendronate Is a Specific, Nanomolar Inhibitor of Farnesyl Diphosphate Synthase
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., & Rodan, G. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1502 · Cited by 402
Guijarro, C., Blanco-Colio, L. M., Ortego, M., Alonso, C., Ortiz, A., Plaza, J. J., Díaz, C., Hernández, G., & Egido, J. (1998) · Circulation Research · doi:10.1161/01.res.83.5.490 · Cited by 390
Laufs, U., Fata, V. L., & Liao, J. K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31725 · Cited by 387
Regulation of Raf-Akt Cross-talk
Moelling, K., Schad, K., Bosse, M., Zimmermann, S., & Schweneker, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111974200 · Cited by 387
Sepp‐Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, W. W., Oliff, A. I., & Rosen, N. X. (1995) · PubMed · Cited by 383
Laufs, U., Marra, D., Node, K., & Liao, J. K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21926 · Cited by 380
Carcinogenicity of Lipid-Lowering Drugs
Newman, T. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530250059028 · Cited by 380
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., Trepel, J. B., Liang, B., Patronas, N., Venzon, D. J., et al. (1996) · PubMed · Cited by 362
Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26802 · Cited by 361
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Wassmann, S., Laufs, U., Bäumer, A. T., Müller, K., Konkol, C., Sauer, H., Böhm, M., & Nickenig, G. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12257-2 · Cited by 345
Rao, S., Porter, D. C., Chen, X., Herliczek, T., Lowe, M., & Keyomarsi, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.14.7797 · Cited by 345
p70s6k function is essential for G1 progression
Lane, H. A., Fernandez, A., Lamb, N. J. C., & Thomas, G. (1993) · Nature · doi:10.1038/363170a0 · Cited by 345
Post-translational modifications of p21rho proteins.
Adamson, P., Marshall, C. J., Hall, A., & Tilbrook, P. A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)88661-1 · Cited by 335
Blais, L., Desgagné, A., & LeLorier, J. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2363 · Cited by 326
THE POTENTIAL OF FARNESYLTRANSFERASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS
Gibbs, J. B., & Oliff, A. (1997) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.37.1.143 · Cited by 324
Ashar, H. R., James, L., Gray, K., Carr, D., Black, S., Armstrong, L., Bishop, W. R., & Kirschmeier, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003469200 · Cited by 321
Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27.
Katayose, Y., Kim, M., Rakkar, A. N. S., Li, Z., Cowan, K. H., & Seth, P. K. (1997) · PubMed · Cited by 313
Ras and Rho regulation of the cell cycle and oncogenesis
Pruitt, K., & Der, C. J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00528-6 · Cited by 311
Rho signals to cell growth and apoptosis
Aznar, S., & Lacal, J. C. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00412-8 · Cited by 310
Liu, M., Bryant, M., Chen, J., Lee, S., Yaremko, B., Lipari, P., Malkowski, M. G., Ferrari, E., Nielsen, L. L., Prioli, N. A., et al. (1998) · PubMed · Cited by 309
Assessing possible hazards of reducing serum cholesterol
Law, M. R., Thompson, S. G., & Wald, N. J. (1994) · BMJ · doi:10.1136/bmj.308.6925.373 · Cited by 309
Double-Edged Role of Statins in Angiogenesis Signaling
Urbich, C., Dernbach, E., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000014081.30867.f8 · Cited by 305
Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect
Inoue, I., Goto, S.-I., Mizotani, K., Awata, T., Mastunaga, T., Kawai, S.-I., Nakajima, T., Hokari, S., Komoda, T., & Katayama, S. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00680-9 · Cited by 298
Cell cycle-specific effects of lovastatin.
Jakóbisiak, M., Bruno, S., Skierski, J. S., & Darzynkiewicz, Z. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3628 · Cited by 295
A cell cycle-regulated inhibitor of cyclin-dependent kinases.
Hengst, L., Dulic, V, Slingerland, J. M., Lees, E., & Reed, S. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5291 · Cited by 287
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., deSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., & Lee, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.9141 · Cited by 285
Amin, D., Cornell, S., Gustafson, S., Needle, S., Ullrich, J., Bilder, G., & Perrone, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41388-4 · Cited by 281
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204146 · Cited by 279
Park, H.-J., Kong, D., Iruela-Arispe, L., Begley, U., Tang, D., & Galper, J. B. (2002) · Circulation Research · doi:10.1161/01.res.0000028149.15986.4c · Cited by 276
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Shepherd, J., Blauw, G. J., & Murphy, M. B. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00040-0 · Cited by 273
Hsp90 and Caveolin Are Key Targets for the Proangiogenic Nitric Oxide–Mediated Effects of Statins
Brouet, A., Sonveaux, P., Dessy, C., Moniotte, S., Balligand, J.-L., & Feron, O. (2001) · Circulation Research · doi:10.1161/hh2201.100319 · Cited by 269
Zujewski, J., Horak, I. D., Bol, C. J., Woestenborghs, R., Bowden, C., End, D. W., Piotrovsky, V. K., Chiao, J., Belly, R. T., Todd, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.927 · Cited by 264
Cholesterol and Alzheimer’s disease: Is there a link?
Simons, M., Keller, P., Dichgans, J., & Schulz, J. B. (2001) · Neurology · doi:10.1212/wnl.57.6.1089 · Cited by 257
Critical role of Rho in cell transformation by oncogenic Ras.
Prendergast, G. C., Khosravi‐Far, R., Solski, P. A., Kurzawa, H., Lebowitz, P. F., & Der, C. J. (1995) · PubMed · Cited by 253
Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells.
Agarwal, B., Bhendwal, S., Halmos, B., Moss, S. F., Ramey, W. G., & Holt, P. R. (1999) · PubMed · Cited by 251
Du, W., Lebowitz, P. F., & Prendergast, G. C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1831 · Cited by 248
Rikitake, Y. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00468-8 · Cited by 246
Adjei, A. A., Erlichman, C., Davis, J. N., Cutler, D. L., Sloan, J. A., Marks, R. S., Hanson, L. J., Svingen, P. A., Atherton, P. J., Bishop, W. R., et al. (2000) · PubMed · Cited by 242
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336
Hoover, R. R., Mahon, F.-X., Melo, J. V., & Daley, G. Q. (2002) · Blood · doi:10.1182/blood.v100.3.1068 · Cited by 241
Pfeffer, M. A., Keech, A., Sacks, F. M., Cobbe, S. M., Tonkin, A., Byington, R. P., Davis, B. R., Friedman, C. P., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000017634.00171.24 · Cited by 241
Jiang, K., Coppola, D., Crespo, N. C., Nicosia, S. V., Hamilton, A. D., Sebti, S. M., & Cheng, J. Q. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.139-148.2000 · Cited by 240
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239
Lerner, E. C., Zhang, T.-T., Knowles, D. B., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1997) · Oncogene · doi:10.1038/sj.onc.1201296 · Cited by 239
CENP-E as an Essential Component of the Mitotic Checkpoint In Vitro
Abrieu, A., Kahana, J. A., Wood, K. W., & Cleveland, D. W. (2000) · Cell · doi:10.1016/s0092-8674(00)00070-2 · Cited by 239
Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., & Garcia, A. M. (1995) · PubMed · Cited by 238
Hirai, A., Nakamura, S., Noguchi, Y., Yasuda, T., Kitagawa, M., Tatsuno, I., Oeda, T., Tahara, K., Terano, T., Narumiya, S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.13 · Cited by 235
Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201656 · Cited by 230
Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1995) · PubMed · Cited by 227
Lebowitz, P. F., Davide, J. P., & Prendergast, G. C. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6613 · Cited by 221
Dimitroulakos, J., Nohynek, D., Backway, K. L., Hedley, D. W., Yeger, H., Freedman, M. H., Minden, M. D., & Penn, L. Z. (1999) · Blood · doi:10.1182/blood.v93.4.1308 · Cited by 219
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
Xia, Z., Tan, M., Wei-Lynn Wong, W., Dimitroulakos, J., Minden, M., & Penn, L. (2001) · Leukemia · doi:10.1038/sj.leu.2402196 · Cited by 218
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., Inoue, M., & Nakamura, H. (2002) · Gastroenterology · doi:10.1053/gast.2002.31093 · Cited by 217
Shipman, C. M., Croucher, P. I., Russell, R. G. G., Helfrich, M. H., & Rogers, M. J. (1998) · PubMed · Cited by 216
Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB
Lebowitz, P. F., Casey, P. J., Prendergast, G. C., & Thissen, J. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15591 · Cited by 216
INCIDENCE OF CANCER IN MEN ON A DIET HIGH IN POLYUNSATURATED FAT
Lee Pearce, M., & Dayton, S. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91086-5 · Cited by 215
Sun, J., Blaskovich, M. A., Knowles, D. B., Qian, Y., Ohkanda, J., Bailey, R. D., Hamilton, A. D., & Sebti, S. M. (1999) · PubMed · Cited by 213
Nègre-Aminou, P., van Vliet, A. K., van Erck, M., van Thiel, G. C. F., van Leeuwen, R. E. W., & Cohen, L. H. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00184-1 · Cited by 212
Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP.
Marcelli, M., Cunningham, G. R., Haidacher, S. J., Padayatty, S. J., Sturgis, L., Kagan, C., & Denner, L. A. (1998) · PubMed · Cited by 210
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D.-S., Danishefsky, S. J., & Rosen, N. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1369 · Cited by 210
Prendergast, G. C., Davide, J. P., deSolms, S. J., Giuliani, E. A., Graham, S. L., Gibbs, J. B., Oliff, A., & Kohl, N. E. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4193 · Cited by 209
Non-Ras targets of farnesyltransferase inhibitors: focus on Rho
Lebowitz, P. F., & Prendergast, G. C. (1998) · Oncogene · doi:10.1038/sj.onc.1202175 · Cited by 209
Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., et al. (2003) · Blood · doi:10.1182/blood-2002-07-1973 · Cited by 206
Vincent, L., Chen, W., Hong, L., Mirshahi, F., Mishal, Z., Mirshahi-Khorassani, T., Vannier, J.-P., Soria, J., & Soria, C. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02337-7 · Cited by 201
Blanco-Colio, L. M., Villa, A., Ortego, M., Hernández-Presa, M. A., Pascual, A., Plaza, J. J., & Egido, J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00613-x · Cited by 200
Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J., & Sebti, S. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000145200 · Cited by 198
Bernhard, E. J., McKenna, W. G., Hamilton, A. D., Sebti, S. M., Qian, Y., Wu, J., & Muschel, R. J. (1998) · PubMed · Cited by 195
Do statins cause cancer? A meta-analysis of large randomized clinical trials
Bjerre, L. M., & LeLorier, J. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00705-7 · Cited by 195
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0224 · Cited by 195
Weber, J. D., Hu, W., Jefcoat, S. C., Raben, D. M., & Baldassare, J. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.32966 · Cited by 193
Vogt, A., Sun, J., Qian, Y., Hamilton, A. D., & Sebti, S. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27224 · Cited by 190
Kusama, T., Mukai, M., Iwasaki, T., Tatsuta, M., Matsumoto, Y., Akedo, H., & Nakamura, H. (2001) · PubMed · Cited by 187
Agarwal, B., Rao, C. V., Bhendwal, S., Ramey, W. R., Shirin, H., Reddy, B. S., & Holt, P. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70342-2 · Cited by 185
Lebowitz, P. F., Sakamuro, D., & Prendergast, G. C. (1997) · PubMed · Cited by 181
Rao, S., Lowe, M., Herliczek, T. W., & Keyomarsi, K. (1998) · Oncogene · doi:10.1038/sj.onc.1202322 · Cited by 180
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Wang, E.-J., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 176
Lovastatin Induces Growth Inhibition and Apoptosis in Human Malignant Glioma Cells
Jones, K. D., Couldwell, W. T., Hinton, D. R., Su, Y. H., He, S. K., Anker, L., & Law, R. E. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2861 · Cited by 176
Cohen, S. J., Ho, L., Ranganathan, S., Abbruzzese, J. L., Alpaugh, R. K., Beard, M., Lewis, N. L., McLaughlin, S., Rogatko, A., Perez-Ruixo, J. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.040 · Cited by 174
Peters, D. G., Hoover, R. R., Gerlach, M. J., Koh, E. Y., Zhang, H., Choe, K., Kirschmeier, P., Bishop, W. R., & Daley, G. Q. (2001) · Blood · doi:10.1182/blood.v97.5.1404 · Cited by 173
Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., et al. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.85 · Cited by 171
DELETION OF THE CHOLESTEROL-NEGATIVE FEEDBACK SYSTEM IN LIVER TUMORS.
Siperstein, M. D., & Fagan, V. M. (1964) · PubMed · Cited by 168
CAAX Geranylgeranyl Transferase Transfers Farnesyl as Efficiently as Geranylgeranyl to RhoB
Armstrong, S. A., Hannah, V. C., Goldstein, J. L., & Brown, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.7864 · Cited by 164
Dimitroulakos, J., Ye, L. Y., Benzaquen, M., Moore, M. J., Kamel‐Reid, S., Freedman, M. H., Yeger, H., & Penn, L. Z. (2001) · PubMed · Cited by 164
Vogt, A., Qian, Y., McGuire, T. F., Hamilton, A. D., & Sebti, S. M. (1996) · PubMed · Cited by 164
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen, S. S., Väänänen, H. K., Härkönen, P. L., & Lakkakorpi, P. T. (2002) · PubMed · Cited by 162
Du, W., & Prendergast, G. C. (1999) · PubMed · Cited by 160
Lee, S. J., Ha, M. J., Lee, J., Nguyen, P., Choi, Y. H., Pirnia, F., Kang, W.-K., Wang, X.-F., Kim, S.-J., & Trepel, J. B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10618 · Cited by 160
Liu, A.-X., Du, W., Liu, J.-P., Jessell, T. M., & Prendergast, G. C. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.6105-6113.2000 · Cited by 158
Regulation of Raf by Akt Controls Growth and Differentiation in Vascular Smooth Muscle Cells
Reusch, H. P., Zimmermann, S., Schaefer, M., Paul, M., & Moelling, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105322200 · Cited by 158
The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard, E. J., Kao, G. D., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., & McKenna, W. G. (1996) · PubMed · Cited by 155
Wong, B., Lumma, W. C., Smith, A. M., Sisko, J. T., Wright, S. D., & Cai, T. (2001) · Journal of Leukocyte Biology · doi:10.1189/jlb.69.6.959 · Cited by 154
Novel Tricyclic Inhibitors of Farnesyl Protein Transferase
Bishop, W. R., Bond, R. W., Petrin, J., Wang, L., Patton, R., Doll, R. J., Njoroge, G. F., Catino, J. J., Schwartz, J. L., Windsor, W. T., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.51.30611 · Cited by 153
Alonso, D. F., Fariña, H. G., Skilton, G., Gabri, M. R., Lorenzo, M. S. D., & Gomez, D. E. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006058409974 · Cited by 146
Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lü, S., Malumbres, M., Gibbs, W. W., Oliff, A. I., & Pellicer, À. (1998) · PubMed · Cited by 146
Cholesterol inhibition, cancer, and chemotherapy
Buchwald, H. (1992) · The Lancet · doi:10.1016/0140-6736(92)90744-n · Cited by 146
Inhibition of Isoprenoid Biosynthesis Induces Apoptosis in Human Promyelocytic HL-60 Cells
Pérez‐Sala, D., & Mollinedo, F. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1359 · Cited by 144
A Phase I-II Trial of Lovastatin for Anaplastic Astrocytoma and Glioblastoma Multiforme
Larner, J. M., Jane, J., Laws, E. R., Packer, R. J., Myers, C. E., & Shaffrey, M. E. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199812000-00010 · Cited by 142
Farnesyl transferase inhibitors: a novel targeted therapy for cancer
Johnston, S. R. D. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00191-1 · Cited by 141
Michikawa, M., & Yanagisawa, K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722278.x · Cited by 140
Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma
Kim, W. S., Kim, M. M., Choi, H. J., Yoon, S., Lee, M. H., Park, K., Park, C. H., & Kang, W. K. (2001) · Investigational New Drugs · doi:10.1023/a:1006481423298 · Cited by 137
Carlberg, M., Dricu, A., Blegen, H., Wang, M., Hjertman, M., Zickert, P., Höög, A., & Larsson, O. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.29.17453 · Cited by 137
Feleszko, W., Młynarczuk-Biały, I., Bałkowiec-Iskra, E., Czajka, A., Świtaj, T., Stokłosa, T., Giermasz, A., & Jakóbisiak, M. (2000) · PubMed · Cited by 134
Inhibition of ras prenylation: A novel approach to cancer chemotherapy
Sebti, S. M., & Hamilton, A. D. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00014-4 · Cited by 133
Bouterfa, H., Sattelmeyer, V., Czub, S., Vordermark, D., Roosen, K., & Tonn, J. (2000) · PubMed · Cited by 131
Crul, M., de Klerk, G. J., Swart, M., Veer, L. J. V., de Jong, D., Boerrigter, L., Palmer, P. A., Bol, C. J., Tan, H., GAST, G. C. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.116 · Cited by 131
Inhibition of cell growth by lovastatin is independent of ras function.
DeClue, J. E., Vass, W. C., Papageorge, A. G., Lowy, D. R., & Willumsen, B. M. (1991) · PubMed · Cited by 131
Manne, V., Yan, N., Jm, C., Av, T., Ricca, C. S., Brown, J. G., Andahazy, M., Schmidt, R. J., Patel, D. V., & Zahler, R. (1995) · PubMed · Cited by 131
Vincent, L., Soria, C., Mirshahi, F., Opolon, P., Mishal, Z., Vannier, J., Soria, J., & Li, H. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012283.15789.67 · Cited by 129
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin
Wong, W. W.-L., Tan, M. M., Xia, Z., Dimitroualakos, J., Minden, M. D., & Penn, L. Z. (2001) · PubMed · doi:10.5167/uzh-58181 · Cited by 129
NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action
Husain, S. S., Szabó, I., & Tarnawski, A. S. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05528.x · Cited by 128
Crespo, N. C., Ohkanda, J., Yen, T. J., Hamilton, A. D., & Sebti, S. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006213200 · Cited by 127
The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells
van de Donk, N. W. C. J., Kamphuis, M., Lokhorst, H. M., & Bloem, A. C. (2002) · Leukemia · doi:10.1038/sj.leu.2402501 · Cited by 127
Maltese, W. A., Defendini, R., Green, R. A., Sheridan, K. M., & Donley, D. K. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112165 · Cited by 125
Kurzrock, R., Kantarjian, H. M., Cortes, J. E., Singhania, N., Thomas, D. A., Wilson, E. F., Wright, J. J., Freireich, E. J., Talpaz, M., & Sebti, S. M. (2003) · Blood · doi:10.1182/blood-2002-11-3359 · Cited by 125
Miller, A. C., Karikó, K., Myers, C. E., Clark, E. P., & Samid, D. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910530222 · Cited by 123
Danen, E. H. J., Sonneveld, P., Sonnenberg, A., & Yamada, K. M. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.7.1413 · Cited by 120
Eskens, F. A. L. M., Awada, A. H., Cutler, D. L., de Jonge, M. J. A., Luyten, G. P. M., Faber, M. N., Statkevich, P., Sparreboom, A., Verweij, J., Hanauske, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1167 · Cited by 117
Sepp‐Lorenzino, L., & Rosen, N. X. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20243 · Cited by 117
RhoA Stimulates p27Kip Degradation through Its Regulation of Cyclin E/CDK2 Activity
Hu, W., Bellone, C. J., & Baldassare, J. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.6.3396 · Cited by 116
Prasanna, P., Thibault, A., Liu, L., & Samid, D. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020710.x · Cited by 114
Reichert, A., Heisterkamp, N., Daley, G. Q., & Groffen, J. (2001) · Blood · doi:10.1182/blood.v97.5.1399 · Cited by 114
The role of p21ras in receptor tyrosine kinase signalling
Pronk, G. J. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90010-8 · Cited by 113
Shi, B., Yaremko, B., Hajian, G., Terracina, G., Bishop, W. R., Liu, M., & Nielsen, L. L. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000170 · Cited by 113
Feldkamp, M. M., Lau, N. C., & Guha, A. (1999) · Oncogene · doi:10.1038/sj.onc.1203105 · Cited by 113
Current status of clinical trials of farnesyltransferase inhibitors
Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., & End, D. W. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00009 · Cited by 112
Suzuki, N., Urano, J., & Tamanoi, F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15356 · Cited by 109
Tanaka, T., Tatsuno, I., Uchida, D., Moroo, I., Morio, H., Nakamura, S., Noguchi, Y., Yasuda, T., Kitagawa, M., Saito, Y., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-08-02852.2000 · Cited by 109
Ashar, H. R., James, L. J., Gray, K., Carr, D. M., McGuirk, M., Maxwell, E., Black, S., Armstrong, L., Doll, R. J., Taveras, A. G., et al. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5076 · Cited by 109
James, G. L., Brown, M. S., Cobb, M. H., & Goldstein, J. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47043-3 · Cited by 108
Rose, W. C., Lee, F. Y., Fairchild, C. R., Lynch, M. J., Monticello, T. M., Kramer, R. A., & Manne, V. (2001) · PubMed · Cited by 108
Inhibition of pancreatic adenocarcinoma cell growth by lovastatin
Sumi, S., Beauchamp, R. D., Townsend, C. M., Uchida, T., Murakami, M., Rajaraman, S., Ishizuka, J., & Thompson, J. C. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90032-t · Cited by 107
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line
Ghosh, P., Ghosh‐Choudhury, N., Moyer, M. L., Mott, G. E., Thomas, C. A., Foster, B. A., Greenberg, N. M., & Kreisberg, J. I. (1999) · Oncogene · doi:10.1038/sj.onc.1202792 · Cited by 107
Edamatsu, H., Gau, C., Nemoto, T., Guo, L., & Tamanoi, F. (2000) · Oncogene · doi:10.1038/sj.onc.1203625 · Cited by 107
Omer, C. A., Chen, Z., Diehl, R. E., Conner, M. W., Chen, H. Y., Trumbauer, M. E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M. T., et al. (2000) · PubMed · Cited by 105
Yang, Z., Kozai, T., van der Loo, B., Viswambharan, H., Lachat, M. L., Turina, M. I., Maliñski, T., & Lüscher, T. F. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00924-4 · Cited by 104
Lovastatin Induces Apoptosis in Malignant Mesothelioma Cells
Rubins, J. B., Greatens, T. M., Kratzke, R. A., Tan, A., Polunovsky, V. A., & Bitterman, P. B. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709020 · Cited by 102
Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle Cells
Degraeve, F., Bolla, M., Blaie, S., Créminon, C., Quéré, I., Boquet, P., Levy-Toledano, S., Bertoglio, J. H., & Habib, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104197200 · Cited by 100
Chemical biology of protein isoprenylation/methylation
Rando, R. R. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(95)00233-2 · Cited by 98
Kèlland, L. R., Smith, V., Valenti, M. R., Patterson, L., Clarke, P. A., DETRE, S. I., End, D. W., Howes, A. J., Dowsett, M., Workman, P., et al. (2001) · PubMed · Cited by 96
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733)
Hidaka, Y., Eda, T., Yonemoto, M., & Kamei, T. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90179-k · Cited by 95
Adjei, A. A., Davis, J. N., Bruzek, L. M., Erlichman, C., & Kaufmann, S. H. (2001) · PubMed · Cited by 95
Knapp, A. C., Huang, J., Starling, G. C., & Kiener, P. A. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00462-1 · Cited by 95
Epidemiological and Clinical Aspects of Nonsteroidal Anti-inflammatory Drugs and Cancer Risks
Moran, E. M. (2002) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v21.i2.130 · Cited by 92
Feldkamp, M. M., Lau, N. C., Roncari, L., & Guha, A. (2001) · PubMed · Cited by 92
Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung, S. J., Xu, G., Pan, J., Christgen, M., & Bamiagis, A. (2000) · PubMed · Cited by 92
Sebti, S. M., Tkalcevic, G. T., & Jani, J. P. (1991) · Cancer Communications · doi:10.3727/095535491820873371 · Cited by 92
Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells
Agarwal, B., Halmos, B., Feoktistov, A. S., Protiva, P., Ramey, W. G., Chen, M., Pothoulakis, C., LaMont, J. T., & Holt, P. R. (2002) · Carcinogenesis · doi:10.1093/carcin/23.3.521 · Cited by 89
Hahn, S. M., Bernhard, E. J., Regine, W. F., Mohiuddin, M., Haller, D. G., Stevenson, J. P., Smith, D., Pramanik, B., Tepper, J. E., DeLaney, T. F., et al. (2002) · PubMed · Cited by 89
Coxon, F. P., Benford, H. L., Russell, R. G. G., et al. (1998) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)13063-5 · Cited by 89
Gray-Bablin, J., Rao, S., & Keyomarsi, K. (1997) · PubMed · Cited by 87
Statin use, hyperlipidaemia, and the risk of breast cancer
Kaye, J. A., Meier, C. R., Walker, A. M., & Jick, H. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600267 · Cited by 87
Cholesterol and mevalonic acid modulation in cell metabolism and multiplication
Soma, M. R., Corsini, A., & Paoletti, R. (1992) · Toxicology Letters · doi:10.1016/0378-4274(92)90167-i · Cited by 87
Vidal, A., Millard, S. S., Miller, J. P., & Koff, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112090200 · Cited by 86
Regulation of Ras-related RhoB protein expression during the cell cycle.
Zalcman, G., Closson, V., Linares‐Cruz, G., Lerebours, F., Honoré, N., Tavitian, A., & Olofsson, B. (1995) · PubMed · Cited by 86
Direct Effects of Statins on the Vascular Wall
Corsini, A., Pazzucconi, F., Arnaboldi, L., Pfister, P., Fumagalli, R., Paoletti, R., & Sirtori, C. R. (1998) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199805000-00017 · Cited by 86
Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice
Feleszko, W., Zagożdżon, R., Gołąb, J., & Jakóbisiak, M. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10034-x · Cited by 85
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells
Tamanoi, F., Gau, C. ‐., Jiang, C., Edamatsu, H., & Kato‐Stankiewicz, J. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000802 · Cited by 84
Law, B. K., Waltner-Law, M. E., Entingh, A. J., Chytil, A. M., Aakre, M. E., Nørgaard, P. H., & Moses, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005545200 · Cited by 80
Lovastatin-induced Apoptosis of Human Medulloblastoma Cell Lines in vitro
Macaulay, R. J. B., Wang, W., Dimitroulakos, J., Becker, L. E., & Yeger, H. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006164406202 · Cited by 78
Cited by
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E., & Lippman, S. M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1751 · Cited by 819
Hutchinson–Gilford progeria syndrome: Review of the phenotype
Hennekam, R. C. M. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31346 · Cited by 575
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Statin Drugs and Risk of Advanced Prostate Cancer
Platz, E. A., Leitzmann, M. F., Visvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj499 · Cited by 406
Metadata
- Authors
- Graaf, M. R., Richel, D. J., van Noorden, C. J. F., & Guchelaar, H.-J.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2004-11
- Volume
- 30
- Issue
- 7
- Pages
- 609-641
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W1966383174
- Cited by
- 300
- References
- 268
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.